Evaluation of Genomic Applications in Practice and Prevention (EGAPP™)
In 2004, the Centers for Disease Control and Prevention launched the EGAPP initiative to establish and test a systematic, evidence-based process for evaluating genetic tests and other applications of genomic technology that are in transition from research to clinical and public health practice.
A key EGAPP goal is to provide objective, timely, and credible information that is clearly linked to available scientific evidence. This information will allow health care providers and payers, consumers, policymakers, and others to distinguish genetic tests that are safe and useful.
How EGAPP Works
- EGAPP Steering Committee
The EGAPP Steering Committee is a federal, interagency group that oversees the recruitment and selection of the independent EGAPP Working Group members.
- EGAPP Working Group
The EGAPP Working Group is an independent group that develops recommendations and evidence-based reviews on genetic tests. To be considered for membership on the EGAPP Working Group please complete the nomination process.
- CDC Summaries of EGAPP Recommendation Statements
- CDC-sponsored EGAPP evidence reports
- EGAPP initiative poster [PDF 233KB]
- EGAPP Working Group Independent Web site
- Informing the effective integration of genomics into health practice—Lynch syndrome
- ACCE Model for Evaluating Genetic Tests
- Recommendations by the EGAPP Working Group